BrainsWay (BWAY) announced the launch of a multicenter clinical trial investigating the use of its novel Deep TMS 360 system in individuals with Alcohol Use Disorder, AUD. AUD represents a major economic and health burden, affecting about 29 million Americans and, despite available treatments, up to 60% of patients relapse within 3-6 months. This study will mark the first multicenter clinical trial utilizing BrainsWay’s next-generation multichannel TMS platform, representing a major milestone in advancing the company’s innovation pipeline.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- Brainsway’s Market Expansion and Strong Revenue Performance Justify Buy Rating
- Brainsway price target raised to $18 from $17 at H.C. Wainwright
- BrainsWay Gains FDA Approval for Adolescent Depression Treatment
- Brainsway’s Deep TMS device granted FDA clearance in Major Depressive Disorder
- BrainsWay’s Q3 2025 Earnings Call Highlights Growth